#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	11126	16S	1529	1529	99.93	16S.l6.c17.ctg.1	2483	548.6	0	.	n	.	0	C1450T	SNP	1450	1450	C	1848	1848	T	786	T,C,A	783,2,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	11126	16S	1529	1529	99.93	16S.l6.c17.ctg.1	2483	548.6	1	SNP	n	C1184T	0	.	.	1184	1184	C	1582	1582	C	698	C	698	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	11126	16S	1529	1529	99.93	16S.l6.c17.ctg.1	2483	548.6	0	HET	.	.	.	A263G	.	263	263	A	661	661	A	625	A,G	350,275	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	19236	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4310	556.3	0	.	n	.	0	C265T	SNP	265	265	C	1025	1025	T	697	T,C,G,A	688,5,2,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	19236	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4310	556.3	0	.	n	.	0	G1337A	SNP	1337	1337	G	2097	2097	A	705	A,C	704,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	19236	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4310	556.3	0	.	n	.	0	T1971C	SNP	1971	1971	T	2731	2731	C	696	C,T	694,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	19236	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4310	556.3	1	SNP	n	A2045G	0	.	.	2045	2045	A	2805	2805	A	623	A,C	620,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	19236	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4310	556.3	1	SNP	n	C2597T	0	.	.	2597	2597	C	3357	3357	C	639	C,T,G	637,1,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
blaTEM.WHO_M_pConjugative_00003	blaTEM.WHO_M_pConjugative_00003	1	0	27	24722	blaTEM	861	861	100.0	blaTEM.l15.c4.ctg.1	2168	1421.4	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Betalactam resistance
folP.WHO_V_01427c	folP.WHO_V_01427c	1	1	27	1648	folP	855	855	100.0	folP.l15.c4.ctg.1	2009	102.2	1	SNP	p	R229S	1	.	.	685	687	AGC	1278	1280	AGC	157;157;157	A,G;G;C,A,G	156,1;157;155,1,1	folP.WHO_V_01427c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	3912	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3973	122.7	1	SNP	p	S91F	0	.	.	271	273	TCC	871	873	TCC	154;152;152	T;C;C	154;152;152	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	3912	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3973	122.7	1	SNP	p	D95G	0	.	.	283	285	GAC	883	885	GAC	157;157;157	G;A;C	157;157;157	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	3912	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3973	122.7	1	SNP	p	D95N	0	.	.	283	285	GAC	883	885	GAC	157;157;157	G;A;C	157;157;157	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	1574	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1845	106.2	0	.	p	.	0	A39T	NONSYN	115	117	GCC	698	700	ACC	164;166;170	A,C;C;C	163,1;166;170	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	1574	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1845	106.2	0	.	p	.	0	L47P	NONSYN	139	141	CTC	722	724	CCC	180;182;180	C;C;C,A	180;182;179,1	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	1574	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1845	106.2	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	896	898	CAC	199;203;205	C,T;A;C	198,1;203;205	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	1574	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1845	106.2	1	SNP	p	G45D	0	.	.	133	135	GGC	716	718	GGC	177;179;177	G;G;C	177;179;177	mtrR.WHO_V_01454:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	910	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c17.ctg.1	1542	73.5	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	3798	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3469	136.4	0	.	p	.	0	V384I	NONSYN	1150	1152	GTC	1773	1775	ATC	158;158;158	A;T;C	158;158;158	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	3798	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3469	136.4	1	SNP	p	D86N	0	.	.	256	258	GAC	879	881	GAC	181;183;182	G;A;C,T,G	180;182;179,1,1	parC.WHO_F_01444:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	3798	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3469	136.4	1	SNP	p	S87I	0	.	.	259	261	AGT	882	884	AGT	183;182;180	A;G;T	182;181;179	parC.WHO_F_01444:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	3798	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3469	136.4	1	SNP	p	S87W	0	.	.	259	261	AGT	882	884	AGT	183;182;180	A;G;T	182;181;179	parC.WHO_F_01444:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	3798	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3469	136.4	1	SNP	p	S87R	0	.	.	259	261	AGT	882	884	AGT	183;182;180	A;G;T	182;181;179	parC.WHO_F_01444:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	3798	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3469	136.4	1	SNP	p	S88P	0	.	.	262	264	TCC	885	887	TCC	179;179;177	T;C;C,G	178;178;174,2	parC.WHO_F_01444:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	3412	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3192	133.3	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1830	1832	GGC	175;173;172	G;G;C	175;173;172	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.12.001	penA.12.001	1	1	27	3100	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2902	133.2	1	SNP	p	A311V	0	.	.	931	933	GCA	1491	1493	GCA	197;197;199	G;C,G,A;A	197;195,1,1;198	penA.12.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3100	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2902	133.2	1	SNP	p	I312M	0	.	.	934	936	ATC	1494	1496	ATC	198;199;198	A,C;T,C;C	196,1;198,1;197	penA.12.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3100	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2902	133.2	1	SNP	p	V316T	0	.	.	946	948	GTG	1506	1508	GTG	210;211;212	G,C,A;T;G	208,1,1;211;212	penA.12.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3100	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2902	133.2	1	SNP	p	V316P	0	.	.	946	948	GTG	1506	1508	GTG	210;211;212	G,C,A;T;G	208,1,1;211;212	penA.12.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3100	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2902	133.2	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2010	2012	ACC	190;187;186	A;C,T;C,T	190;186,1;185,1	penA.12.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3100	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2902	133.2	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2064	2066	GCG	156;157;159	G,A;C,A;G	154,1;155,1;158	penA.12.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3100	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2902	133.2	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2064	2066	GCG	156;157;159	G,A;C,A;G	154,1;155,1;158	penA.12.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3100	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2902	133.2	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2187	2189	GGC	178;179;181	G,A;G;C,G	177,1;179;180,1	penA.12.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3100	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2902	133.2	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2196	2198	GGC	176;176;174	G;G,T;C,T	176;175,1;173,1	penA.12.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3100	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2902	133.2	1	SNP	p	P552S	1	.	.	1654	1656	TCG	2214	2216	TCG	171;172;169	T,G;C;G	170,1;172;169	penA.12.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	4422	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3682	149.6	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1917	1919	CCG	188;187;186	C;C,A;G	188;186,1;186	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	1768	porA	1146	1146	99.65	porA.l15.c4.ctg.1	2317	95.1	0	.	p	.	0	M83fs	FSHIFT	247	247	A	824	824	C	128	C	128	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	560	222	porB1a	984	287	90.38	porB1a.l6.c17.ctg.2	298	22.2	0	.	p	.	0	H217N	NONSYN	649	651	CAT	35	37	AAT	11;11;11	A;A;T	11;11;11	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	560	222	porB1a	984	287	90.38	porB1a.l6.c17.ctg.2	298	22.2	0	.	p	.	0	D218N	NONSYN	652	654	GAT	38	40	AAT	11;11;11	A;A;T	11;11;11	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	560	222	porB1a	984	287	90.38	porB1a.l6.c17.ctg.2	298	22.2	0	.	p	.	0	V226A	NONSYN	676	678	GTA	62	64	GCA	11;11;11	G;C;A	11;11;11	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	560	222	porB1a	984	287	90.38	porB1a.l6.c17.ctg.2	298	22.2	0	.	p	.	0	.	MULTIPLE	700	702	ACT	85	87	GTA	11;11;11	G;T;A	11;11;11	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	560	222	porB1a	984	287	90.38	porB1a.l6.c17.ctg.2	298	22.2	0	.	p	.	0	S236N	NONSYN	706	708	AGC	91	93	AAC	11;11;11	A;A,C;C	11;10,1;11	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	560	222	porB1a	984	287	90.38	porB1a.l6.c17.ctg.2	298	22.2	0	.	p	.	0	.	MULTIPLE	709	711	AAC	95	99	TGGCG	11;11;11;11;11	T;G;G;C;G	11;11;11;11;11	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	560	222	porB1a	984	287	90.38	porB1a.l6.c17.ctg.2	298	22.2	0	.	p	.	0	D238A	NONSYN	712	714	GAT	101	103	GCT	11;11;11	G,C;C;T	10,1;11;11	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	560	222	porB1a	984	287	90.38	porB1a.l6.c17.ctg.2	298	22.2	0	.	p	.	0	A251V	NONSYN	751	753	GCG	140	142	GTA	14;14;15	G;T;A	14;14;15	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	560	222	porB1a	984	287	90.38	porB1a.l6.c17.ctg.2	298	22.2	0	.	p	.	0	S271T	NONSYN	811	813	TCG	200	202	ACT	42;42;42	A;C,G;T	42;41,1;42	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	560	222	porB1a	984	287	90.38	porB1a.l6.c17.ctg.2	298	22.2	0	.	p	.	0	Y273D	NONSYN	817	819	TAT	206	208	GAT	42;42;42	G;A;T	42;42;42	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	560	222	porB1a	984	287	90.38	porB1a.l6.c17.ctg.2	298	22.2	0	.	p	.	0	D276N	NONSYN	826	828	GAT	215	217	AAC	42;42;42	A;A;C	42;42;42	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	560	222	porB1a	984	287	90.38	porB1a.l6.c17.ctg.2	298	22.2	0	.	p	.	0	N277H	NONSYN	829	831	AAC	218	220	CAC	42;42;42	C;A;C	42;42;42	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2364	porB1b	1035	1035	97.69	porB1b.l6.c17.ctg.1	2072	141.9	0	.	p	.	0	V45I	NONSYN	133	135	GTT	675	677	ATT	212;211;209	A;T,A;T,C	212;210,1;208,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2364	porB1b	1035	1035	97.69	porB1b.l6.c17.ctg.1	2072	141.9	0	.	p	.	0	E210_Y211insG	INS	628	628	G	1170	1170	G	179	G	179	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2364	porB1b	1035	1035	97.69	porB1b.l6.c17.ctg.1	2072	141.9	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	1176	1176	T	179	T	179	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2364	porB1b	1035	1035	97.69	porB1b.l6.c17.ctg.1	2072	141.9	1	SNP	p	G120K	0	.	.	358	360	GGT	900	902	GGT	202;201;203	G;G,A;T	202;200,1;203	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2364	porB1b	1035	1035	97.69	porB1b.l6.c17.ctg.1	2072	141.9	1	SNP	p	A121N	0	.	.	361	363	GCC	903	905	GCC	200;200;198	G;C,T;C	200;198,2;198	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2364	porB1b	1035	1035	97.69	porB1b.l6.c17.ctg.1	2072	141.9	1	SNP	p	A121D	0	.	.	361	363	GCC	903	905	GCC	200;200;198	G;C,T;C	200;198,2;198	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	7502	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5448	171.7	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2324	2326	CAT	178;177;180	C;A;T	178;177;180	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1080	rpsJ	312	312	100.0	rpsJ.l15.c30.ctg.1	1726	77.9	1	SNP	p	V57M	1	.	.	169	171	ATG	867	869	ATG	200;200;204	A,G;T,G;G	199,1;199,1;204	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
